n2pharma.co.uk valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot /
BingBot /
BaiduSpider /
YandexBot /
Meta Tags
Title COVID-19 and N2-01 - N2
Description TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM TECHNOLOGY COVID-19 Close × TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM COVID-19 treatment candidate Severity,
Keywords N/A
Server Information
WebSite n2pharma faviconn2pharma.co.uk
Host IP 195.24.68.9
Location Russian Federation
Related Websites
Site Rank
More to Explore
n2pharma.co.uk Valuation
US$1,365
Last updated: 2022-07-17 10:44:12

n2pharma.co.uk has Semrush global rank of 0. n2pharma.co.uk has an estimated worth of US$ 1,365, based on its estimated Ads revenue. n2pharma.co.uk receives approximately 157 unique visitors each day. Its web server is located in Russian Federation, with IP address 195.24.68.9. According to SiteAdvisor, n2pharma.co.uk is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$1,365
Daily Ads Revenue US$1
Monthly Ads Revenue US$37
Yearly Ads Revenue US$453
Daily Unique Visitors 10
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
n2pharma.co.uk. A 3598 IP: 195.24.68.9
n2pharma.co.uk. NS 3600 NS Record: ns8.nic.ru.
n2pharma.co.uk. NS 3600 NS Record: ns4.nic.ru.
n2pharma.co.uk. NS 3600 NS Record: ns3.nic.ru.
n2pharma.co.uk. MX 3600 MX Record: 20 mx03.nicmail.ru.
n2pharma.co.uk. MX 3600 MX Record: 5 mx02.nicmail.ru.
n2pharma.co.uk. MX 3600 MX Record: 10 mx01.nicmail.ru.
n2pharma.co.uk. TXT 3600 TXT Record: v=spf1 redirect=nicmail.ru
HtmlToTextCheckTime:2022-07-17 10:44:12
TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM TECHNOLOGY COVID-19 Close × TECHNOLOGY COVID-19 OTHER APPLICATIONS TEAM COVID-19 treatment candidate Severity, morbidity and mortality of COVID-19 are linked to endothelial dysfunction N2-01 has proven to reduce the level of endothelial dysfunction both in laboratory settings and clinical usage MHRA confirmed the plausibility of these scientific arguments and reduced the requirements for initial testing N2-01 is already proven to be safe and effective in veterinary applications related to endothelial dysfunction Available not-for-profit to patients with COVID-19, if proven effective More about the role of the endothelium COVID-19 treatment candidate Severity, morbidity and mortality of COVID-19 are linked to endothelial dysfunction N2-01 has proven to reduce the level of endothelial dysfunction both in laboratory settings and clinical usage MHRA confirmed the plausibility of these scientific arguments and reduced the requirements for initial
HTTP Headers
HTTP/1.1 301 Moved Permanently
Server: openresty/1.19.9.1
Date: Tue, 02 Nov 2021 16:16:35 GMT
Content-Type: text/html; charset=iso-8859-1
Connection: keep-alive
Location: https://n2pharma.co.uk/

HTTP/2 200 
server: openresty/1.19.9.1
date: Tue, 02 Nov 2021 16:16:36 GMT
content-type: text/html; charset=UTF-8
content-length: 55707
accept-ranges: bytes